Ozmosi | Beclometasone Drug Profile
Drug Profile
Using advanced filters...

Beclometasone

Alternative Names: beclometasone, beclomethasone, agn-208397, agn 208397, agn208397, beclometasona, qvar redihaler, qnasl, beconase aq, qvar 40, beclovent, qvar 80, beconase, vanceril, vancenase, vanceril double strength, vancenase aq, qvar 100
Clinical Status: Inactive
Latest Update: 2026-09-21
Latest Update Note: Clinical Trial Update

Product Description

Beclomethasone is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. After cell surface receptor attachment and cell entry, beclomethasone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. Beclomethasone is a 17alpha-hydroxy steroid that is prednisolone in which the hydrogens at the 9alpha and 16beta positions are substituted by a chlorine and a methyl group, respectively. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Beclomethasone)

Mechanisms of Action: Steroid Receptor Agonist, Immunosuppressive

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant, Oral

FDA Designation: *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Company: Chiesi
Company Location: Europe
Company Founding Year: 1935
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Beclometasone

Countries in Clinic: Argentina, Bulgaria, Canada, China, Czech Republic, Hungary, Mexico, Poland, Puerto Rico, Romania, Spain, United States

Active Clinical Trial Count: 9

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Asthma|Chronic Obstructive Pulmonary Disease|Colitis, Ulcerative|Conjunctivitis, Allergic|Spasm

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2025-521230-29-00

2025-521230-29-00

P3

Not yet recruiting

Conjunctivitis, Allergic

2029-09-01

2017-000330-61

BeCalCU

P3

Active, not recruiting

Colitis, Ulcerative

2018-01-05

2025-06-05

Treatments

NCT07768891

BT-BF-IA-Ⅲ

P3

Recruiting

Asthma

2028-06-01

63%

2026-08-18

Primary Endpoints|Treatments

NCT04320342

TRITON

P3

Completed

Chronic Obstructive Pulmonary Disease

2026-01-12

88%

2026-09-22

Primary Endpoints|Start Date

NCT05292586

FORCE2

P3

Completed

Asthma

2024-06-24

93%

2025-09-05

CTR20131574

CTR20131574

P3

Active, not recruiting

Asthma

None

2025-04-29

Patient Enrollment|Treatments

CTR20131558

CTR20131558

P3

Recruiting

Asthma|Spasm

None

2025-04-29

Patient Enrollment|Treatments

CTR20131559

CTR20131559

P3

Recruiting

Asthma|Spasm

None

2025-04-29

Patient Enrollment|Treatments

CTR20131557

CTR20131557

P3

Recruiting

Spasm|Asthma

None

2025-04-29

Patient Enrollment|Treatments